Incidence of residual neuromuscular blockade in a post-anaesthetic care unit

Anaesthesia and Intensive Care

Volumn 38, Issue 1, 2010, Pages 91-95

  Yip, P C ^a   Hannam, J A ^b   Cameron, A J D ^a   Campbell, D ^a  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Post anaesthetic care unit; Residual neuromuscular blockade

Indexed keywords

ATRACURIUM; MUSCLE RELAXANT AGENT; NEOSTIGMINE; NEUROMUSCULAR BLOCKING AGENT; ROCURONIUM; SUXAMETHONIUM; VECURONIUM;

ADULT; AGED; ARTICLE; ASSISTED VENTILATION; CLINICAL ASSESSMENT; CONFIDENCE INTERVAL; ELECTROMYOGRAPHY; FEMALE; GENERAL ANESTHESIA; HOSPITAL DISCHARGE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NEUROMUSCULAR BLOCKING; OBSERVATIONAL STUDY; POSTOPERATIVE COMPLICATION; PROSPECTIVE STUDY; RECOVERY ROOM; TERTIARY HEALTH CARE;

EID: 75749118516     PISSN: 0310057X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0310057x1003800116     Document Type: Article

References (26)

1. Murphy GS. Residual neuromuscular blockade: incidence, assessment and relevance in the postoperative period. Minerva Anestesiologica 2006; 72:97-109.
2. Ali HH, Utting JE, Gray TC. Quantitative assessment of residual antidepolarizing block (part ii). Br J Anaesth 1971; 43:478-485.
3. Eriksson li, Sundman E, Olsson R, Nilsson l, Witt H, Ekberg O et al. Functional assessment of pharynx at rest and during swallowing in partially paralyzed humans: simultaneous videomanometry and mechanomyography of awake human volunteers. Anesthesiology 1997; 87:1035-1043.
4. Eriksson li, Sato M, Severinghaus JW. Effect of a vecuronium-induced partial neuromuscular block on hypoxic ventilatory response. Anesthesiology 1993; 78:693-699.
5. Herbstreit F, Peters J, Eikermann M. impaired upper airway integrity by residual neuromuscular blockade: increased airway collapsibility and blunted genioglossus muscle activity in response to negative pharyngeal pressure. Anesthesiology 2009; 110:1253-1260.
6. Berg H, Viby-Mogensen J, Roed J, Mortensen CR, Engboek J, Skovgaard lT et al. Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomised and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand 1997; 41:1095-1103.
7. Murphy GS, Szokol JW, Marymont JH, Greenberg SB, Avram MJ, Vender JS. Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. Anesth Analg 2008; 107:130-137.
8. Kopman AF, Zank lM, Ng J, Neuman GG. Antagonism of cisatracurium and rocuronium block at a tactile train-of-four count of 2: should quantitative assessment of neuromuscular function be mandatory? Anesth Analg 2004; 98:102-106.
9. Debaene B, Plaud B, Dilly MP, Donati F. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology 2003; 98:1042-1048.
10. Hayes AH, Mirakhur RK, Breslin DS, Reid JE, McCourt KC. Postoperative residual block after intermediate-acting neuromuscular blocking drugs. Anaesthesia 2001; 56:312-318.
11. Aldrete JA. The post-anesthesia recovery score revisited. J Clin Anesth 1995; 7:89-91.
12. Naguib M, Kopman AF, Ensor JE. Neuromuscular monitoring and postoperative residual curarisation: a meta-analysis. Br J Anaesth 2007; 98:302-316.
13. Baillard C, Gehan G, Reboul-Marty J, larmignat P, Samama CM, Cupa M. Residual curarization in the recovery room after vecuronium. Br J Anaesth 2000; 84:394-395.
14. McCaul C, Tobin E, Boylan JF, McShane AJ. Atracurium is associated with postoperative residual curarization. Br J Anaesth 2002; 89:766-769.
15. Product Information on Tracrium, GlaxoSmithKline Australia Pty ltd.
16. Viby-Mogensen J, Engbaek J, Eriksson li, Gramstad l, Jensen E, Jensen FS et al. Good clinical research practice (GCRP) in pharmacodynamic studies of neuromuscular blocking agents. Acta Anaesthesiol Scand 1996; 40:59-74.
17. Cheeseman JF, Merry AF, Pawley MD, de Souza Rl, Warman GR. The effect of time of day on the duration of neuromuscular blockade elicited by rocuronium blockade. Anaesthesia 2007; 62:1114-1120.
18. Kopman AF, Eikermann M. Antagonism of non-depolarising neuromuscular block: current practice. Anaesthesia 2009; 64 (Suppl 1):22-30.
19. Viby-Mogensen J, Jensen NH, Engbaek J, Ording H, Skovgaard lT, Chraemmer-Jorgensen B. Tactile and visual evaluation of the response to train-of-four nerve stimulation. Anesthesiology 1985; 63:440-443.
20. Eriksson Li. Evidence-based practice and neuromuscular monitoring: it's time for routine quantitative assessment. Anesthesiology 2003; 98:1037-1039.
21. Mortensen CR, Berg H, el-Mahdy A, Viby-Mogensen J. Perioperative monitoring of neuromuscular transmission using acceleromyography prevents residual neuromuscular block following pancuronium. Acta Anaesthesiol Scand 1995; 39:797-801.
22. Murphy GS, Szokol JW, Marymont JH, Greenberg SB, Avram MJ, Vender JS et al. Intraoperative acceleromyographic monitoring reduces the risk of residual neuromuscular blockade and adverse respiratory events in the postanesthesia care unit. Anesthesiology 2008; 109:389-398.
23. de Boer HD, van Egmond J, van de Pol F, Bom A, Booij lH. Sugammadex, a new reversal agent for neuromuscular block induced by rocuronium in the anaesthetized Rhesus monkey. Br J Anaesth 2006; 96:473-479.
24. White PF, Tufanogullari B, Sacan O, Pavlin EG, Viegas OJ, Minkowitz HS et al. The effect of residual neuromuscular blockade on the speed of reversal with sugammadex. Anesth Analg 2009; 108:846-851.
25. Australian and New Zealand College of Anaesthetists. Recommendations on Monitoring During Anaesthesia. From www.anzca.edu.au/resources/professional- documents/professional-standards/ps18.html Accessed June 2009.
26. The Royal College of Anaesthetists. Recommendations for standards of monitoring during anaesthesia and recovery. From www.rcoa.ac.uk/index.asp? SectioniD=3 Accessed June 2009.